Research programme: autoimmune disorders therapeutics - Mount Tam BiotechnologiesAlternative Names: TAM-01; TAM-02; TAM-03
Latest Information Update: 15 Feb 2017
At a glance
- Originator Biotica Technology; University of Cambridge
- Developer Mount Tam Biotechnologies
- Class Macrolides; Polyketides
- Mechanism of Action Immunosuppressants; MTOR protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic lupus erythematosus
- Research Cancer; Multiple sclerosis